Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Carbamazepine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A known ✓ | P35499 | 1/20 | 0.43 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.43 |
| ▸ | SCN9A known ✓ | Q15858 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CACNA2D1 | P54289 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 10/20 | 0.37 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbamazepine SCHEMBL7185280 | 0.87 | LMNA (0.56) | LMNATSHRMAPK1SCN4ASCN5A | |
| Gabapentin SCHEMBL876152 | 0.82 | CACNA2D1 (0.61) | LMNATSHRMAPK1CACNA2D1SMN1; SMN2 | |
| Oxcarbazepine SCHEMBL28141318 | 0.68 | ALDH1A1 (0.63) | LMNATSHRMAPK1CACNA2D1SMN1; SMN2 | |
| Pregabalin SCHEMBL3672687 | 0.67 | CACNA2D1 (0.73) | LMNATSHRCACNA2D1SMN1; SMN2CACNB3 | |
| Gabapentin SCHEMBL2862353 | 0.67 | ALDH1A1 (0.92) | LMNATSHRMAPK1CACNA2D1SMN1; SMN2 | |
| Gabapentin SCHEMBL14966637 | 0.66 | ALDH1A1 (0.58) | LMNATSHRCACNA2D1SMN1; SMN2USP2 | |
| Gabapentin SCHEMBL14967717 | 0.66 | ALDH1A1 (0.58) | LMNATSHRCACNA2D1SMN1; SMN2USP2 | |
| Carbamazepine SCHEMBL4593916 | 0.66 | LMNA (0.85) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL28220906 | 0.65 | LMNA (0.92) | LMNATSHRMAPK1SCN4ASCN5A | |
| Carbamazepine SCHEMBL29433237 | 0.65 | LMNA (1.00) | LMNATSHRMAPK1SCN4ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1272218-A2 | A PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ACUTE, CHRONIC PAIN AND/OR NEUROPATHIC PAIN AND MIGRAINES | Pfizer Products Inc. (US) | 2003-01-08 | — | — | EP | claimed |
| WO-2001076576-A2 | A PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ACUTE, CHRONIC PAIN AND/OR NEUROPATHIC PAIN AND MIGRAINES | PFIZER PRODUCTS INC. (US) | 2001-10-18 | — | — | WO | claimed |